Meeting
2019 ASCO Annual Meeting
A phase I multiple-dose escalation study to assess the safety, tolerability, and pharmacokinetics of VEGF-receptor inhibitor telatinib (EOC315) in Chinese patients with advanced solid tumors.
Authors
Hongming Pan
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
Hongming Pan , Tianshu Liu , Jason Tsai , Yapeng Zhao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Conduct of Clinical Research
Clinical Trial Registration Number
NCT03175497
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3061)
DOI
10.1200/JCO.2019.37.15_suppl.3061
Abstract #
3061
Poster Bd #
53
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.
First Author: Melissa Lynne Johnson
Poster
2017 ASCO Annual Meeting
A phase I, open-label, first-time-in-patient dose escalation and expansion study to assess the safety, tolerability, and pharmacokinetics of nanoparticle encapsulated Aurora B kinase inhibitor AZD2811 in patients with advanced solid tumours.
First Author: Howard A. Burris III
Poster
2017 ASCO Annual Meeting
A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors.
First Author: Sarina Anne Piha-Paul
Poster
2023 ASCO Annual Meeting
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.
First Author: Yan Zhang